Business
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a p...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico\n\n\n\n MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (\"Knight\"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi\n \n ®\n \n (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V.\n \n\n Minjuvi\n \n ®\n \n in combination with lenalidomide, followed by Minjuvi\n \n ®\n \n monotherapy, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autologous stem cell transplantation (ASCT).\n \n\n DLBCL is the most common subtype of non-Hodgkin lymphoma, presenting an aggressive clinical profile. While a significant number of patients can be cured with standard front-line therapy, many will develop refractory disease or relapse following an initial response, and these individuals are often ineligible for ASCT. Such patients face a very poor prognosis, emphasizing the need for treatment options to improve their outcomes\n \n 1\n \n .\n \n\n The marketing authorization approval was based on the data from L-MIND trial, an open label, multicenter, single arm Phase 2 study, that evaluated Minjuvi\n \n ®\n \n in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL ineligible for ASCT. The study primary analysis results demonstrated an objective response rate (ORR, primary endpoint) of 60%, including a complete response rate (CR) of 43% and a disease control rate (DCR) of 74%\n \n 2\n \n . According to the 2025 National Comprehensive Cancer Network (NCCN) Guidelines, Minjuvi\n \n ®\n \n is listed as one of the preferred second-line treatments for DLBCL patients who are ineligible for transplantation\n \n 3\n \n .\n \n\n “The treatment of DLBCL has significantly evolved in recent years, particularly in the relapse/refractory setting. I am glad to have more tools for our patients, as half of those who relapse after first-line therapy are not candidates for autologous transplantation. For these patients, there are new and effective options including Minjuvi\n \n ®\n \n , achieving high rates of long-lasting responses. Approximately 57% of responding patients were still in remission at 5 y...